胰岛素抵抗对基本高血压患者左心室重塑的影响:一个横截面研究
Bernard Kianu Phanzu1, Aliocha Nkodila Natuhoyila2, Eleuthère Kintoki Vita3
1Department of Internal Medicine, Division of Cardiology, University of Kinshasa Hospital, Kinshasa, Democratic Republic of the Congo; Centre Médical de Kinshasa, Kinshasa, Democratic Republic of the Congo.
Cardiovascular journal of Africa
|June 27, 2023
概括
胰岛素抵抗和胰岛素高血压对左心室缩的影响不同. 胰岛素耐药性会影响左心室末端-透缩直径,而高胰岛素血症会影响后壁厚度,这两者都会导致透缩功能障碍.
科学领域:
- 心脏病学 心脏病学
- 内分泌学 在内分泌学.
- 内部医学 内部医学
背景情况:
- 左心室缩 (LVH) 在临床上使用不完美的物理和心电学标准进行评估.
- 心声学通过使用Devereux公式计算的左心室质量来定义LVH,该质量受胰岛素抵抗和胰岛素高血压的影响.
- 胰岛素耐药性和高胰岛素血症在LVH发展和扩张功能障碍中的不同作用仍然不清楚.
研究的目的:
- 评估胰岛素耐药性 (使用胰岛素耐药性的恒常模型评估 - HOMAIR) 和空腹血胰岛素水平与Devereux配方成分和左心室扩张功能参数的关联.
- 阐明胰岛素耐药性和高胰岛素血症对高血压患者左心室几何形状和扩张功能的具体贡献.
主要方法:
- 收集了220名高血压患者的临床数据.
- 利用后勤回归模型测试胰岛素耐药性标记物 (HOMAIR,禁食胰岛素) 与Devereux的配方成分和扩张功能参数之间的关联.
主要成果:
- 胰岛素水平和HOMAIR解释了46.8%的腹腔隔膜直径变化和30.9%的E波减速时间变化.
- 仅HOMAIR就解释了左心室终端-透气直径变化的30.1%.
- 仅胰岛素水平就解释了46.3%的后壁厚度和29.4%的相对壁壁厚度变化.
结论:
- 胰岛素抵抗和胰岛素高血压对左心室缩组件产生不同影响.
- 胰岛素抵抗影响左心室末端-透气直径,而高胰岛素血症影响后壁厚度.
- 胰岛素抵抗和高胰岛素血症都会导致腹膜间隔膜的变化和腹功能障碍.
相关概念视频
01:29Heart Failure II: Pathophysiology
16
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
16
01:29Cardiomyopathy III: Hypertrophic Cardiomyopathy
17
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
17
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
467
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
467
01:17Pathophysiology of Heart Failure
1.7K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.7K
01:20Mitral Regurgitation I: Introduction
19
Mitral regurgitation is characterized by the backward circulation of blood from the left ventricle to the left atrium during systole, a phase of the cardiac cycle when the heart contracts and pumps blood out of the chambers. This abnormal flow occurs primarily due to the dysfunction of the mitral valve or its supporting structures, which include the mitral leaflets, chordae tendineae, annulus, and papillary muscles.Etiology and Mechanisms:Primary Mitral Regurgitation: This type arises from...
19
01:30Heart Failure V: Medical Management
15
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
15